- Home
- CII vs PHAT Comparison
CII vs PHAT Comparison
Compare CII & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CII | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 963.2M | 1.0B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CII | PHAT |
|---|---|---|
| Price | $22.54 | $11.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.33 |
| AVG Volume (30 Days) | 78.8K | ★ 933.6K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $147,190,000.00 |
| Revenue This Year | N/A | $221.87 |
| Revenue Next Year | N/A | $80.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $16.76 | $2.21 |
| 52 Week High | $19.81 | $18.31 |
Technical Indicators
Market Signals| Indicator | CII | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 38.10 |
| Support Level | $22.39 | $11.83 |
| Resistance Level | $23.25 | $13.17 |
| Average True Range (ATR) | 0.32 | 0.74 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 8.25 | 21.85 |
Price Performance
Historical ComparisonAbout CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.